πŸ‡ΊπŸ‡Έ FDA
Patent

US 10793543

Selective C-KIT kinase inhibitor

granted A61KA61K31/445A61K31/45

Quick answer

US patent 10793543 (Selective C-KIT kinase inhibitor) held by HEFEI GRACEVO BIO-MEDICINE CO., LTD expires Mon Oct 01 2040 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
HEFEI GRACEVO BIO-MEDICINE CO., LTD
Grant date
Tue Oct 06 2020 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Oct 01 2040 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
8
CPC classes
A61K, A61K31/445, A61K31/45, A61K31/454, A61K31/4545